- Published on
Ophthalmology – Clinically Significant Diabetic Macular Edema (CSME)
Clinically significant diabetic macular edema (CSME) is a vision-threatening form of diabetic macular edema defined by the Early Treatment Diabetic Retinopathy Study (ETDRS). It is present when there is retinal thickening within 500 microns of the center of the fovea, hard exudates within 500 microns of the foveal center with adjacent retinal thickening, or an area of retinal thickening at least one disc area in size with any part located within one disc diameter of the foveal center. CSME may be focal, resulting from leakage from isolated microaneurysms, or diffuse, due to generalized breakdown of the inner blood-retinal barrier.
CSME is the leading cause of visual loss in patients with diabetes. Its frequency increases with longer duration of diabetes and with more severe diabetic retinopathy. Studies have shown that a substantial proportion of both type 1 and type 2 diabetic patients develop CSME over time, and hundreds of thousands of individuals are affected in the United States alone.
Major risk factors include long-standing diabetes, poor glycemic control, hypertension, hyperlipidemia, nephropathy, proteinuria, and more advanced diabetic retinopathy. In patients with adult-onset diabetes, insulin use has also been associated with higher risk. Pregnancy can accelerate diabetic retinopathy and CSME, so careful ophthalmic monitoring is recommended before and throughout pregnancy.
The pathophysiology of CSME reflects chronic hyperglycemia-induced damage to the retinal microvasculature. This includes pericyte loss, thickening of the capillary basement membrane, endothelial dysfunction, leukostasis, oxidative stress, and increased inflammatory cytokines such as VEGF. These changes lead to breakdown of the blood-retinal barrier and leakage of fluid into the macula. In some cases, vitreomacular traction may also contribute to edema formation.
Patients may not always notice symptoms early, but a careful history should assess diabetes duration and control, insulin dependence, hypertension, lipid disorders, and kidney disease. Clinically, CSME is diagnosed by slit-lamp biomicroscopy, sometimes aided by contact lens examination, which demonstrates retinal thickening in the macular area. The severity of diabetic retinopathy and the presence of vitreomacular interface abnormalities should also be documented.
Ancillary testing is helpful for both evaluation and follow-up. Fluorescein angiography is not necessary to make the diagnosis, but it can identify leaking microaneurysms, diffuse leakage, areas of macular ischemia, and capillary nonperfusion. Optical coherence tomography (OCT) is especially valuable for documenting retinal thickening, identifying epiretinal membranes or vitreomacular traction, and monitoring treatment response. Systemic evaluation should include HbA1c, blood pressure, blood lipids, and renal function.
Treatment begins with optimization of systemic disease, including strict control of blood glucose, blood pressure, and lipids. Traditionally, focal laser photocoagulation has been the first-line ocular treatment and has been shown to reduce the risk of visual loss substantially. More recently, intravitreal anti-VEGF agents such as ranibizumab and bevacizumab have become important options and may be superior to laser alone in many cases. Intravitreal corticosteroids can also be useful, especially in selected patients, though they are generally considered adjunctive therapy.
In cases of diffuse CSME, refractory edema, or associated vitreomacular traction, referral to a vitreoretinal specialist is appropriate. Vitrectomy with membrane peeling may benefit patients with persistent edema related to traction or epiretinal membrane formation. Fenofibrate may also reduce the need for laser in some diabetic patients.
Close follow-up is essential because CSME is often chronic and recurrent. Patients undergoing active treatment are commonly reviewed every 1 to 3 months, and those with severe nonproliferative or proliferative diabetic retinopathy generally require dilated examination every 3 to 4 months. Coordination with the patient’s primary care physician or endocrinologist is an important part of management.
The prognosis depends on the duration and severity of edema, associated retinal ischemia, and response to treatment. Without treatment, many patients experience moderate visual loss over time. Laser therapy significantly lowers this risk, and newer therapies may further improve outcomes.
0 Comments
